A 6-months Observational Study to Evaluate the Quality of Life of Patients Treated With Phytotherapy or Alpha-blockers for Benign Prostatic Hyperplasia

CompletedOBSERVATIONAL
Enrollment

288

Participants

Timeline

Start Date

June 22, 2022

Primary Completion Date

July 29, 2024

Study Completion Date

July 29, 2024

Conditions
Benign Prostatic Hyperplasia
Interventions
DRUG

Phytotherapy

Phytotherapy or alphablockers

Trial Locations (31)

Unknown

Medical Office of Delsart MD, Bersée

Medical Office of Breton MD, Béziers

Medical Office of Guiu MD, Ferrals-les-Corbières

Medical Office of Patron MD, Gap

Medical Office of Coulon MD, Giromagny

Medical Office of Dassa MD, Istres

Medical Office of Rigaud MD, Lamagistère

Medical Office of Specht MD, Lambersart

Medical Office of Mesguich MD, Le Blanc-Mesnil

Medical Office of Dassonval MD, Marles-les-Mines

Medical Office of Cayron MD, Montpellier

Medical Office of Chassagne MD, Montpellier

Medical Office of Baranes MD, Paris

Medical Office of Labregere MD, Paris

Medical Office of Merlin MD, Raimbeaucourt

Medical Office of Lemercier MD, Royan

Medical Office of Margueritte MD, Six-Fours-les-Plages

Maison de Santé MEDIVIE, Templeuve-en-Pévèle

Medical Office of Demoulin MD, Val-de-Vesle

Medical Office of David MD, Verzy

Cs Vargas, Santander, Santander

C.S. San Jose, A Coruña

C.S. Zona Ii, Albacete

C.S. Aldea Moret, Cáceres

C.S. Fuencarral, Madrid

C.S. Mendiguchia, Madrid

Centro Urología, Andrología Y Salud Sexual, Palma de Mallorca

C.S. Rotxapea, Pamplona

C.S. Soria Rural, Soria

C.S. Laguna de Duero, Valladolid

Cs Villamayor de Gallego, Zaragoza

All Listed Sponsors
collaborator

Kappa Santé

INDUSTRY

lead

Pierre Fabre Medicament

INDUSTRY